-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Amneal Pharmaceuticals with Overweight Rating, Announces Price Target of $15

Benzinga·12/09/2025 15:19:55
語音播報
Barclays analyst Glen Santangelo initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight rating and announces Price Target of $15.